Irene Moreno

610 total citations
37 papers, 314 citations indexed

About

Irene Moreno is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Irene Moreno has authored 37 papers receiving a total of 314 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 9 papers in Surgery. Recurrent topics in Irene Moreno's work include Lung Cancer Treatments and Mutations (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Colorectal Cancer Surgical Treatments (4 papers). Irene Moreno is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Colorectal Cancer Surgical Treatments (4 papers). Irene Moreno collaborates with scholars based in Spain, United States and United Kingdom. Irene Moreno's co-authors include Jesús García‐Foncillas, Javier Martínez‐Useros, Cristina Caramés, Bernard Doger, Weiyao Li, Manuel Morales‐Ruiz, Gloria Serrano, Silvia Foti, María Jesús Fernández‐Aceñero and Evan Y. Yu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Irene Moreno

31 papers receiving 310 citations

Peers

Irene Moreno
Yi‐Te Lee United States
Yanli Xiong China
Valentina Viggiani Italy
Travis Rice‐Stitt United States
Elisabet Sanchez United Kingdom
Alessandra R. Garcia United States
Giada Franchi Italy
Elizabeth C. Paver Australia
Jiwu Chang China
Xiaolong Liang China
Yi‐Te Lee United States
Irene Moreno
Citations per year, relative to Irene Moreno Irene Moreno (= 1×) peers Yi‐Te Lee

Countries citing papers authored by Irene Moreno

Since Specialization
Citations

This map shows the geographic impact of Irene Moreno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irene Moreno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irene Moreno more than expected).

Fields of papers citing papers by Irene Moreno

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Irene Moreno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irene Moreno. The network helps show where Irene Moreno may publish in the future.

Co-authorship network of co-authors of Irene Moreno

This figure shows the co-authorship network connecting the top 25 collaborators of Irene Moreno. A scholar is included among the top collaborators of Irene Moreno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Irene Moreno. Irene Moreno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Doger, Bernard, Jeffrey Yachnin, Irene Moreno, et al.. (2025). 581 Preliminary phase 1 results of clinical trial investigating BI-1910, a tumor necrosis factor receptor 2 (TNFR2) agonist, in solid tumor cancer patients. Regular and Young Investigator Award Abstracts. A660–A661.
2.
Harrington, Kevin J., Shigehisa Kitano, Valentina Gambardella, et al.. (2025). Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors. Future Oncology. 21(2). 195–200. 2 indexed citations
3.
Nieto‐Jiménez, Cristina, Bernard Doger, Irene Moreno, et al.. (2025). In silico evaluation of the immunogenic profile of lung cancers with SMARCA4 genetic alterations. Scientific Reports. 15(1). 17832–17832.
4.
Moreno, Irene, Emiliano Calvo, Salvador Fudio, et al.. (2024). Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug–Drug Interaction Study. Marine Drugs. 22(4). 178–178. 3 indexed citations
5.
6.
Hollebecque, Antoine, Efrat Dotan, Chih‐Yi Liao, et al.. (2024). 58 (PB046): Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): the ReFocus study. European Journal of Cancer. 211. 114585–114585. 1 indexed citations
7.
Moreno, Irene, Cristina Nieto‐Jiménez, Bernard Doger, et al.. (2024). Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2. International Journal of Molecular Sciences. 25(4). 2222–2222. 3 indexed citations
8.
Kamath, Suneel D., David Tai, Irene Moreno, et al.. (2023). Abstract OT3-24-01: ReFocus: A Phase 1/2 Study of the Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Advanced Solid Tumors Including Breast Cancer. Cancer Research. 83(5_Supplement). OT3–24.
9.
Moreno, Irene, Emiliano Calvo, Salvador Fudio, et al.. (2023). 679P Lurbinectedin (LRB) pharmacokinetics (PK) and safety when co-administered with itraconazole (ITZ) in patients with advanced solid tumor. Annals of Oncology. 34. S475–S475. 1 indexed citations
10.
Jiménez, Juan Ocaña, et al.. (2022). Can physiological stimulation prior to ileostomy closure reduce postoperative ileus? A prospective multicenter pilot study. Techniques in Coloproctology. 26(8). 645–653. 3 indexed citations
11.
Miguel, Maria J. de, Ana P. Gomes, Valentina Boni, et al.. (2021). Toxicity and antitumor activity of novel agents in elderly patients with cancer included in phase 1 studies. Investigational New Drugs. 39(6). 1694–1701. 1 indexed citations
12.
Gomes, Ana P., Maria J. de Miguel, Valentina Boni, et al.. (2021). A Predictive Score of Antitumour Activity of Novel Agents in Cancer Patients Treated in Early Phase Studies. Oncology. 99(7). 454–463. 1 indexed citations
13.
Martínez‐Useros, Javier, Weiyao Li, Cristina Caramés, et al.. (2020). KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study. Cells. 9(1). 219–219. 54 indexed citations
14.
Miguel, Maria J. de, Bernard Doger, Valentina Boni, et al.. (2020). Increased vulnerability of clinical research units during the COVID‐19 crisis and their protection. Cancer. 126(17). 3907–3911. 10 indexed citations
15.
Miguel, Maria J. de, Irene Moreno, Valentina Boni, et al.. (2020). 592P A predictive score of antitumour activity of novel agents in cancer patients treated in early phase studies. Annals of Oncology. 31. S497–S497. 1 indexed citations
16.
Moreno, Irene, et al.. (2020). 1749P COVID-19 impact and predictive factors for mortality in cancer patients. Annals of Oncology. 31. S1021–S1021.
17.
Martínez‐Useros, Javier, Irene Moreno, María Jesús Fernández‐Aceñero, et al.. (2018). The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer. BMC Cancer. 18(1). 144–144. 10 indexed citations
18.
Bellmunt, Joaquim, Aly‐Khan A. Lalani, Stephanie A. Wankowicz, et al.. (2018). Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. British Journal of Cancer. 119(6). 707–712. 31 indexed citations
19.
Caramés, Cristina, Ion Cristóbal, Pablo Mínguez, et al.. (2016). MicroRNA-31 overexpression is able to predict pathological response and outcome in locally advanced rectal cancer. Annals of Oncology. 27. vi179–vi179. 1 indexed citations
20.
Martínez‐Useros, Javier, María Rodríguez‐Remírez, Irene Moreno, et al.. (2014). DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer. BMC Cancer. 14(1). 965–965. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yi‐Te Lee Breakdown of academic impact, for papers by Yanli Xiong Breakdown of academic impact, for papers by Valentina Viggiani Breakdown of academic impact, for papers by Travis Rice‐Stitt Breakdown of academic impact, for papers by Elisabet Sanchez Breakdown of academic impact, for papers by Alessandra R. Garcia Breakdown of academic impact, for papers by Giada Franchi Breakdown of academic impact, for papers by Elizabeth C. Paver Breakdown of academic impact, for papers by Jiwu Chang Breakdown of academic impact, for papers by Xiaolong Liang
Rankless by CCL
2026